Elevance Health (ELV), a large publicly traded health insurer in the United States, has caught the attention of investors with its strong Value Style Score and promising earnings. With a Value Style Score of A and a VGM Score of A, as well as a Zacks Rank #3 (Hold) rating, ELV has attractive valuation metrics including a forward earnings multiple of 14X, a PEG Ratio of 1.2, a Price/Cash Flow ratio of 12.6X, and a Price/Sales ratio of 0.7X.
One way that ELV stands out is through its strong value investing approach. By analyzing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies attractive and discounted stocks that may have strong potential for growth. This makes ELV an appealing option for value investors who seek to buy stocks at good prices before the broader market recognizes their true value.
In addition to its strong valuation metrics and value investing approach, ELV also has positive earnings growth prospects. For fiscal 2024, 13 analysts have revised their earnings estimate upwards from $35.58 per share to $37.25 per share, with the Zacks Consensus Estimate now at $37.25 per share. This indicates that ELV has an average earnings surprise of 2.8%, making it an attractive option for investors looking for solid fundamentals and potential growth in their portfolios.
Overall, Elevance Health’s impressive Value and VGM Style Scores, positive earnings growth prospects, and noteworthy valuation metrics make it an appealing addition to any investor’s portfolio looking to invest with confidence in the stock market.
For more stock recommendations and analysis on other companies like Elevance Health, investors can turn to Zacks Investment Research for valuable insights on how to make informed investment decisions that align with their goals and risk tolerance.
